key: cord-0869263-hul4miap authors: Pedler, Rebecca L.; Speck, Peter G. title: Marine mollusc extracts—Potential source of SARS‐CoV‐2 antivirals date: 2021-11-02 journal: Rev Med Virol DOI: 10.1002/rmv.2310 sha: ae989c099abd30d63f6f916d1af9797382e391eb doc_id: 869263 cord_uid: hul4miap Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a novel human coronavirus and the causative agent of coronavirus disease 2019 (Covid‐19). There is an urgent need for effective antivirals to treat current Covid‐19 cases and protect those unable to be vaccinated against SARS‐CoV‐2. Marine molluscs live in an environment containing high virus densities (>10(7) virus particles per ml), and there are an estimated 100,000 species in the phylum Mollusca, demonstrating the success of their innate immune system. Mollusc‐derived antivirals are yet to be used clinically despite the activity of many extracts, including against human viruses, being demonstrated in vitro. Hemolymph of the Pacific oyster (Crassostrea gigas) has in vitro antiviral activity against herpes simplex virus and human adenovirus, while antiviral action against SARS‐CoV‐2 has been proposed by in silico studies. Such evidence suggests that molluscs, and in particular C. gigas hemolymph, may represent a source of antivirals for human coronaviruses. respiratory syndrome (MERS-CoV), SARS-CoV and SARS-CoV-2). 13 Human coronaviruses contain characteristic spike glycoproteins embedded within the viral envelope. 14 The SARS-CoV-2 spike glycoprotein facilitates entry into host cells by binding to the angiotensin converting enzyme 2 (ACE-2) receptor on the host cell surface. 15 Host proteases, TMPRSS2 and furin have also been established as important enzymes for priming SARS-CoV-2 spike glycoproteins upon binding to ACE2. 15 Blocking of this binding process, along with other stages of the SARS-CoV-2 infectious cycle (viral uncoating, genome replication and virion release) remain targets for development of new antiviral drugs. 16 An alternative route for SARS-CoV-2 antiviral discovery has been the repurposing of currently approved drugs. [16] [17] [18] Remdesivir is a nucleotide prodrug of an adenosine analogue which inhibits the RNA-dependent RNA polymerase (RdRp) of filoviruses. 17 Promising randomised trials 19, 20 and in vitro studies 21 have led to the approval of remdesivir to treat SARS-CoV-2 infection in Europe and the United States. 17 Despite gaining approval, data from subsequent clinical trials shows remdesivir has failed to emerge as highly efficacious Covid-19 treatment. 22, 23 The antimalaria drug hydroxychloroquine showed promising in vitro activity against SARS-CoV-2 21 however, it has yielded poor results in randomised clinical trials. 24 Several other repurposing targets have been flagged, including favipiravir, lopinavir-ritonavir, ribavirin, ivermectin and oseltamivir. 16, 18, 25 Despite repurposing efforts, robust antiviral treatments for SARS-CoV-2 are yet to be identified. Marine invertebrates represent an almost totally unexploited source of medicinal compounds. 6, [26] [27] [28] Marine invertebrates lack an adaptive immune system and only have the capacity to elicit innate immune responses, [29] [30] [31] despite living in an environment which contains virus particles in the order of >10 7 per ml. 32, 33 This demonstrates the success of their innate immunity, which includes the production of potent antiviral compounds. 28, 30 The nucleosides spongothymidine and spongouridine, which contain D-arabinose rather than D-ribose, were isolated in the 1950s from the marine sponge, Tectitethya crypta (formerly Cryptoethia crypta), and this led to the development of the only marine invertebrate derived antiviral drug currently available on the market, vidarabine. 6, 28, 30 Vidarabine later inspired the design of antiviral drugs, acyclovir, and zidovudine. 28, 34 Acyclovir and vidarabine are both nucleoside analogues which inhibit the nucleic acid synthesis of certain herpesviruses 6,35 while zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI) used in treatment of human immunodeficiency virus (HIV). 36 The success of vidarabine, zidovudine and acyclovir exemplify how marine invertebrates not only represent a direct source of antiviral compounds but can also inspire the synthesis of novel antivirals. Marine organisms of the phylum Mollusca are responsible for much of the diversity among marine invertebrates, and it is estimated there are over 100,000 species of mollusc, 26 some of which live over 400 years, such as the ocean quahog, Arctica islandica. 37 Molluscan antiviral compounds can be sourced exogenously from their algaebased diets, 26 continuously expressed, or transiently expressed in response to viral challenge. 26, 38, 39 Mollusc derived antivirals are yet to be used clinically despite the activity of many extracts, against human viruses, being demonstrated in vitro. 40, 41 As listed in Table 1 45 Early work involving oral administration of aqueous extracts from canned red abalone (Haliotis rufescens), in Swiss mice, showed protection against poliovirus and influenza A. 46, 47 Antiviral activity against poliovirus has also been observed using paolin II, an extract from the Eastern oyster (Crassostrea virginica). 48 The Pacific oyster (Crassostrea gigas) is an economically important marine mollusc cultured globally. 49 The hemolymph of C. gigas has antiviral activity in vitro. [49] [50] [51] The major C. gigas hemolymph protein, cavortin, also exerts an antiviral effect against HSV-1 in Vero cells. 49 The specific mechanism behind cavortin's antiviral activity, along with its bioavailability in cell culture and/or animal models, remains unknown and presents questions for future research. Despite this, a direct virucidal effect of cavortin against HSV-1 has been identified. 49 Time of addition assays have also suggested that cavortin acts on an intracellular stage of HSV-1 infection. 49 Cavortin is a protein of approximately Mr 20,000, containing a single copper/zinc superoxide dismutase (SOD) domain. 52, 53 There is evidence to suggest that the SOD activity of cavortin has been lost in evolution and its primary role is as a metal chaperone. 52 Intracellular zinc can inhibit SARS-CoV enzymes: RNA dependent RNA polymerase, 54 3C-like protease 55 and papain-like protease 2 56 which are important in viral replication. Zinc may also have potential to act as a therapeutic for SARS-CoV-2. [57] [58] [59] The efficacy of zinc as an antiviral for human coronaviruses is improved by coupling with a metal chaperone. 54, 58 C. gigas has a high zinc content 60 and given the suggested role for cavortin as a metal None. The authors declare no conflict of interests. Peter G. Speck was involved in conception, writing and editing. Rebecca L. Pedler was involved in writing and editing. Not applicable. A novel coronavirus outbreak of global health concern Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients A comprehensive review of viral characteristics, transmission, pathophysiology, immune response, and management of SARS-CoV-2 and COVID-19 as a basis for controlling the pandemic World Health Organisation. WHO Coronavirus disease (COVID-19) dashboard; 2021 Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit Ten-year research update review: antiviral activities from marine organisms Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies World Health Organisation. Tracking SARS-CoV-2 Variants; 2021 Rapid screening method for the detection of SARS-CoV-2 variants of concern Covid-19: time for a paradigm change Coronavirus genomics and bioinformatics analysis Structural comparison of the SARS-CoV-2 spike protein relative to other human-infecting coronaviruses SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor An update on antiviral therapy against SARS-CoV-2: how far have we come? Front Pharmacol Lack of effectiveness of repurposed drugs for COVID-19 treatment Compounds with therapeutic potential against novel respiratory 2019 coronavirus Remdesivir for the treatment of Covid-19-final report Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate Covid-19: a randomized clinical trial Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Remdesivir for 5 or 10 days in patients with severe Covid-19 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial Is oseltamivir suitable for fighting against COVID-19: in silico assessment, in vitro and retrospective study Molluscan biological and chemical diversity: secondary metabolites and medicinal resources produced by marine molluscs Molluscan compounds provide drug leads for the treatment and prevention of respiratory disease Antiviral lead compounds from marine sponges Immune control of herpesvirus infection in molluscs Marine snails and slugs: A great place to look for antiviral drugs Defense mechanisms in farmed marine molluscs High abundance of viruses found in aquatic environments Marine viruses -major players in the global ecosystem New anti-HIV agents and targets The acyclovir legacy: its contribution to antiviral drug discovery Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals Imperceptible senescence: ageing in the ocean quahog Arctica islandica Antiviral immunity in marine molluscs Transcriptome analysis reveals strong and complex antiviral response in a mollusc In vitro antiviral activity against herpes simplex virus in the abalone Haliotis laevigata Screening for antibacterial and antiviral activities in three bivalve and two gastropod marine molluscs Abalone hemocyanin blocks the entry of herpes simplex virus 1 into cells: a potential new antiviral strategy Variation in the antiviral and antibacterial activity of abalone Haliotis laevigata, H. rubra and their hybrid in South Australia Antiviral activity of hemocyanin isolated from marine snail Rapana venosa Antiviral activity of myticin C peptide from mussel: an ancient defense against herpesviruses Antiviral activity of a fraction of abalone juice Antimicrobial effect of abalone juice Chemical studies of Paolin. II. An antiviral substance from oysters Evidence that the major hemolymph protein of the Pacific oyster, Crassostrea gigas, has antiviral activity against herpesviruses Putative antiviral activity in hemolymph from adult Pacific oysters, Crassostrea gigas Evaluation of antiviral activity in hemolymph from oysters Crassostrea rhizophorae and Crassostrea gigas Characterisation of cavortin, the major haemolymph protein of the Pacific oyster (Crassostrea gigas) Evidence in oyster of a plasma extracellular superoxide dismutase which binds LPS Zn 2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture Structural basis of mercury-and zinc-conjugated complexes as SARS-CoV 3C-like protease inhibitors Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): expression, purification, characterization and inhibition Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients Potential interventions for SARS-CoV-2 infections: zinc showing promise Immunopharmacological perspective on zinc in SARS-CoV-2 infection The involvement of zinc transporters in the zinc accumulation in the Pacific oyster Crassostrea gigas Laboratory biosafety measures involving SARS-CoV-2 and the classification as a risk group 3 biological agent Molecular pathology of emerging coronavirus infections Current strategies of antiviral drug discovery for Covid-19 Improved plaque assay for human coronaviruses 229E and OC43 Formulation of abalone hemocyanin with high antiviral activity and stability Antiviral activity of hemocyanin Rapana venosa and its isoforms against Epstein-Barr virus How to cite this article: Pedler RL, Speck PG. Marine mollusc extracts-Potential source of SARS-CoV-2 antivirals